Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Overview of attention for article published in Journal for Immunotherapy of Cancer, February 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 28 X posts from 20 X users, with an upper bound of 33,709 followers.

RT @sitcancer: #JITC: Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1…

RT @sitcancer: #JITC: Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1…

RT @sitcancer: #JITC: Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1…

RT @sitcancer: #JITC: Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 24 additional X posts.